Movement Disorder News and Research

Latest Movement Disorder News and Research

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.

23 Aug 2013

Researcher discovers potential explanation for shizophrenia symptoms

By observing the eye movements of schizophrenia patients while playing a simple video game, a University of British Columbia researcher has discovered a potential explanation for some of their symptoms, including difficulty with everyday tasks.

29 Jul 2013

Great Lakes NeuroTechnologies receives patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received allowance of claims from the U.S. Patent Office for an application covering their system and method of stimulating the brain during sleep to treat movement disorder symptoms.

22 Jul 2013

Experts report lasting benefits of deep brain stimulation in patients with hereditary dystonia

In what is believed to be the largest follow-up record of patients with the most common form of hereditary dystonia - a movement disorder that can cause crippling muscle contractions - experts in deep brain stimulation report good success rates and lasting benefits.

20 Jun 2013

Research: Deep brain stimulation is associated with weight loss trend in morbidly obese patients

The first use of deep brain stimulation to the brain's so-called "feeding center" - the lateral hypothalamic area (LHA) - was associated with a weight loss trend in morbidly obese patients whose stimulation was tuned to increase metabolism with novel guidance from metabolic chamber data, according to a pilot study presented at the International Neuromodulation Society's 11th World Congress by Dr. Michael Oh of the Department of Neurosurgery at the Allegheny General Hospital in Pittsburgh, Pa.

14 Jun 2013

Study suggests promising brain-imaging technique to improve diagnoses of people with movement disorders

A new University of Florida study suggests a promising brain-imaging technique has the potential to improve diagnoses for the millions of people with movement disorders such as Parkinson's disease.

14 Jun 2013

International experts formulate guidance for neuromodulation practitioners

An international panel of experts has formulated guidance for neuromodulation practitioners that reflects increasing recognition of the value of this growing field.

10 Jun 2013

Blocking MHCII action rescues nerve cells from Parkinson's disease mechanisms, researchers find

The same mechanism that lets the immune system mount a massive attack against invading bacteria contributes to the destruction of brain cells as part of Parkinson's disease, according to a study published online today in the Journal of Neuroscience.

5 Jun 2013

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Great Lakes NeuroTechnologies announced today the product launch of Kinesia ProView™ to visualize motor symptom severity response during programming of deep brain stimulation (DBS) for Parkinson’s disease. Kinesia ProView provides a standardized platform to quantitatively assess how symptoms such as tremor, bradykinesia, and dyskinesias change in response to specific DBS settings during outpatient programming procedures.

15 May 2013

Nicotine in peppers and tomatoes may provide protective effect against Parkinson's disease

New research reveals that Solanaceae-a flowering plant family with some species producing foods that are edible sources of nicotine-may provide a protective effect against Parkinson's disease. The study appearing today in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, suggests that eating foods that contain even a small amount of nicotine, such as peppers and tomatoes, may reduce risk of developing Parkinson's.

9 May 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Further research needed into therapeutic potential of rTMS for focal hand dystonia

Repetitive transcranial magnetic stimulation (rTMS) is being increasingly explored as a therapeutic tool for movement disorders associated with deficient inhibition throughout the central nervous system. This includes treatment of focal hand dystonia (FHD), characterized by involuntary movement of the fingers either curling into the palm or extending outward.

11 Apr 2013

St. Jude Medical gets European CE Mark approval for deep brain stimulation systems

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its Brio, Libra and LibraXP deep brain stimulation systems for managing the symptoms of intractable primary and secondary dystonia, a neurological movement disorder that causes a person's muscles to contract and involuntarily spasm, reducing the ability to control movement.

11 Apr 2013

Genetic testing services for rare neurological disorders launched by Athena Diagnostics

Athena Diagnostics, a leader in neurological diagnostics, today announced the clinical availability of new genetic tests to aid the detection of several rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy and certain movement disorders. The lab-developed tests are available through Athena Diagnostics, a business of Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services.

From Quest Diagnostics 19 Mar 2013

Telemedicine house calls may be comparable to in-person care for people with Parkinson’s

A small study of 20 people with Parkinson’s disease suggests that “virtual house calls” using Web-based video conferencing provide clinical benefits comparable to in-person physician office visits, while saving patients and their caregivers time and travel.

12 Mar 2013

Study now tells physicians that dystonia can occur in African-American patients

A pair of studies tells the tale of how a neuroscientist at Mayo Clinic in Florida helped to discover the first African-American family to have inherited the rare movement disorder dystonia, which causes repetitive muscle contractions and twisting, resulting in abnormal posture.

7 Mar 2013

Researchers identify novel signaling pathway responsible for neuroprotective activity of parkin

Researchers from Ludwig-Maximilians-Universitaet (LMU) in Munich identify a novel signal transduction pathway, which activates the parkin gene and prevents stress-induced neuronal cell death.

2 Mar 2013

Emory receives NINDS grant for biomarker research on Parkinson's

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), awarded a three-year, $900,000 grant to the Center for Biomedical Imaging Statistics at Emory's Rollins School of Public Health.

16 Feb 2013

Movement Disorder News and Research

Latest Movement Disorder News and Research

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Researcher discovers potential explanation for shizophrenia symptoms

Great Lakes NeuroTechnologies receives patent for Parkinson’s disease monitoring technology

Experts report lasting benefits of deep brain stimulation in patients with hereditary dystonia

Research: Deep brain stimulation is associated with weight loss trend in morbidly obese patients

Study suggests promising brain-imaging technique to improve diagnoses of people with movement disorders

International experts formulate guidance for neuromodulation practitioners

Blocking MHCII action rescues nerve cells from Parkinson's disease mechanisms, researchers find

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Nicotine in peppers and tomatoes may provide protective effect against Parkinson's disease

BD receives FDA approval for second prefilled injectable drug

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Further research needed into therapeutic potential of rTMS for focal hand dystonia

St. Jude Medical gets European CE Mark approval for deep brain stimulation systems

Genetic testing services for rare neurological disorders launched by Athena Diagnostics

Telemedicine house calls may be comparable to in-person care for people with Parkinson’s

Study now tells physicians that dystonia can occur in African-American patients

Researchers identify novel signaling pathway responsible for neuroprotective activity of parkin

Emory receives NINDS grant for biomarker research on Parkinson's

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Movement Disorder News and Research

Latest Movement Disorder News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in